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Special issue on ALSTremendous progress has been made over the last few years
both in the understanding of the basic mechanisms underlying
motor neuron degeneration in ALS and in the development of
new therapeutic strategies aimed at treating this terrible disease.
Although, to date, only one major gene has been identified as
being causative of ALS, eight additional familial ALS loci have
been identified and five ALS-related genes have been found.
The identification of these additional genes is crucial to fully
elucidating the pathogenic processes underlying ALS. This
special issue reviews the most pertinent areas of research
currently being undertaken in the study of the disease. These
articles have been written by leading experts in the field and
comprehensively cover areas from genetics to the underlying
mechanisms and current treatment strategies.
The most important finding to date has been the identifica-
tion of mutations in the gene encoding mutant superoxide
dismutase-1 (SOD1). Mutations in the SOD1 gene are
responsible for ∼2–3% of ALS cases and most research over
the past 13 years, since the mutations were first found, has
focused on understanding the biological basis of mutant SOD1
neurotoxicity. How does a ubiquitously expressed enzyme
cause specific degeneration of motor neurons? A commonality
between the different mutant SOD1 proteins is their propensity
to misfold and/or to aggregate, and it is now apparent that, like
so many other misfolded proteins associated with disease,
mutant SOD1 elicits its effects through a gain of toxic function
rather through a loss of normal enzymatic activity. The precise
nature of this toxic function has remained elusive and many
downstream pathways have been implicated, including excito-
toxicity, oxidative stress, proteasomal inhibition, defects in
axonal transport, and abnormalities of the cytoskeleton, all of
which are discussed in this issue.
The generation of transgenic mouse models of ALS has
proved invaluable in providing research tools for investigating
disease mechanisms and for testing therapeutics. To this end, the
ALS research field has one of the best models of neurodegen-
eration in the form of transgenic mice expressing mutant SOD1.
No other mouse model so closely recapitulates the disease
features it is meant to represent. Despite the availability of this
model, however, drugs that have shown effectiveness in the
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most cases, treatments are initiated only when there is rampant
disease. Indeed, it is estimated that up to 60% of a patient's
motor neurons have degenerated by the time of diagnosis. This
underscores the need to identify specific biomarkers and/or
other techniques, such as imaging, that will provide a definitive
diagnosis of the disease much sooner.
The nature of the motor neuronal system, which has axonal
process extending from the CNS into the periphery, makes it
amenable to gene therapy strategies by utilizing the retrograde
transport pathway to deliver viral vectors directly to the site of
neurodegeneration. Recent findings have been encouraging, and
clinical trials using this methodology are currently underway.
There is also great hope for stem cell therapies, not only in
replacingmotor neurons but also in improving the neuronalmilieu
by introducing non-neuronal cells genetically engineered to
release neurotrophic factors. It has become increasingly apparent
that non-neuronal cells play an important role in the neurodegen-
erative mechanism in ALS, and therefore supplanting these cells
using stem cell strategies could have therapeutic benefits. A
discussion of these different approaches is provided in this issue.
We have not here specifically addressed the overlap of ALS
with frontotemporal dementia (FTD), which clearly represents a
new and important area of investigation. Recent estimates have
suggested that up to 50% of ALS patients also suffer from
cognitive impairment. Whether these cases signify different
forms of ALS or are a spectrum of the same disease has not yet
been clarified. Nevertheless, studies into understanding the
pathogenic overlap of ALS and FTD are likely to lead to
significant advances in both areas of research.
Finally, we thank Paul Fraser and Pat Crowly for the
opportunity to produce this issue and the staff at Elsevier, who
have been so efficient in bringing it all together. Our thanks also
go to the authors, who, despite their busy schedules, went out of
their way to provide comprehensive and detailed reviews.
Thank you all.
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